News|Articles|June 24, 2025

ADA 2025 Recap: 7 Trials to Know

This recap highlights data on stem cell-derived therapies for type 1 diabetes, cortisol-modulating strategies for hard-to-treat type 2 diabetes, and a novel once-weekly insulin alternative that matches daily injections in efficacy.

The 2025 American Diabetes Association (ADA) Scientific Sessions held June 20–24 in Chicago spotlighted an expanding vision for diabetes and metabolic care that stretches beyond traditional glucose control. This year’s research emphasized regenerative approaches, hormonal targeting, and alternative insulin delivery—all pushing the field toward more individualized, physiology-informed interventions.